贵州百灵企业集团制药股份有限公司股票交易异常波动公告

Group 1 - The company's stock (ST Bailin, code: 002424) experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 12% over two consecutive trading days (June 19 and June 20, 2025) [1] - The company's board confirmed that there were no corrections or supplements needed for previously disclosed information, and no significant undisclosed information that could impact stock prices was found [1][2] - The company's operational situation and external environment have not undergone significant changes, and there are no undisclosed major matters related to the company during the period of stock fluctuation [1][2] Group 2 - The board confirmed that there are no undisclosed matters that should be disclosed according to the Shenzhen Stock Exchange's listing rules, nor any significant information that could impact the company's stock and derivatives trading prices [2] - The company has conducted a self-examination and found no violations of fair information disclosure [3]